Proteostasis Therapeutics Inc. partnered with Biogen Idec to find new drug candidates based on inhibition of Usp14 in a deal worth upward of $200 million. The partnership will pair Proteostasis’ work in protein degradation with Biogen Idec’s expertise in neurodegenerative diseases.